デクスコムジャパン合同会社（本社：東京都目黒区、日本法人社長 浅野 元）は本日、リアルタイムCGM「Dexcom G7 CGMシステム」を発売しました。本製品は2023年9月に製造販売承認を得ており、糖尿病のある方で2歳以上のインスリン自己注射を1日に1回以上行っ ...

Medical device maker DexCom announced Tuesday that the company has received a de novo clearance from the FDA to sell its latest continuous glucose monitoring system — the G6 — that requires no ...

The FDA has officially cleared the Dexcom G5 continuous glucose monitor to inform treatment decisions -- without the use of a fingerstick glucometer, other than for calibration. The G5 has been ...

San Diego’s Dexcom posted a 30 percent jump in revenue for the March quarter as it prepares for a major launch of its next generation continuous glucose monitors that no longer requires finger pricks ...

Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...

Sensor (1), transmitter (2), and a smartphone showing glucose data (3) -- Courtesy of Dexcom Dexcom ($DXCM) had put a bit of a Band-Aid on its mobile strategy--its ...

Dexcom, Inc. DXCM recently announced that its next-generation real-time continuous glucose monitoring (rtCGM) system, DexCom G7, will be available in Canada from Oct 10, for people with any type of ...

Abbott announced Thursday that its continuous glucose monitoring system, requiring no routing fingerstick calibration for type 1 diabetes patients, will now be available to eligible Medicare patients.

Insulet Corporation PODD recently signed a global commercialization deal with Dexcom DXCM to offer an enhanced system of automated insulin delivery. As a result of this partnership, current and future ...